# HemostOD

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hemostod

- Industry: Medical Devices & Equipment
- Headquarters: Switzerland
- Website: www.hemostod.com
- Total disclosed funding: $5.4M
- Latest round: Seed (Oct 1, 2025)
- Investors on record: 2

## About

Based in Switzerland, HemostOD SA specializes in the engineering and manufacturing of advanced platelet therapies to address critical healthcare challenges, particularly focused on thrombocytopenia and immune-refractoriness.HemostOD SA, founded in 2020 in Switzerland, focuses on creating engineered platelets for therapeutic applications. The company has secured CHF 4.3 million in SEED funding, raised on October 1, 2025, led by investors Polytech Ventures and Lichtsteiner Foundation. The founder has a background in biotechnology, contributing to the company's strategic direction.HemostOD specializes in the engineering and manufacturing of universal platelets through its proprietary CAR-PLT technology, addressing critical healthcare challenges such as thrombocytopenia and HLA immune-refractoriness. Their core offerings include targeted delivery of therapeutic cargo, platelet lysate for therapeutic stem cell proliferation, and applications in wound healing, immunomodulation, and anti-inflammatory contexts. Their products cater mainly to clinical partners in Europe and North America, including hospitals and biotech companies.The company operates a B2B model, generating revenue through agreements for the production and supply of engineered platelets. Revenue is also anticipated from joint ventures and collaborations, which may include licensing agreements and service contracts tailored to client needs. The bespoke nature of HemostOD's advanced therapeutic solutions is expected to attract interest from the biopharmaceutical industry.Following the recent SEED funding of CHF 4.3 million in October 2025, HemostOD plans to enhance production capacity of lab-made platelets and prepare for early-stage regulatory requirements. The company is targeting expansions into new geographic markets, particularly in Europe and North America, aiming to increase their footprint within the biopharmaceutical sector.

## Funding rounds

- Seed, Oct 1, 2025, $5.4M — Polytech Ventures, Lichtsteiner Foundation

## Investors

- Polytech Ventures (https://capitalatlas.ai/funds/polytech-ventures) — Seed
- Lichtsteiner Foundation — Seed